Novel Agents in Multiple Myeloma: Exploring Drug Resistance and New Opportunities
Contents
Chair(s)
Giovanni Martinelli
Scientific Director at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.
Claudio Cerchione
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.
Speaker(s)
Claudio Cerchione
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.
Topic: How I manage Multiple Myeloma - State of the art
Topic: How I manage Multiple Myeloma - State of the art
Carolina Terragna
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Italy.
Topic：Molecular biology in myeloma
Topic：Molecular biology in myeloma
Fabio Malavasi
Immunogenetics Laboratory, Department of Medical Sciences, University of Torino, Torino, Italy.
Topic: Anti-CD38 antibody therapy: basic science and combined immunotherapy strategies
Topic: Anti-CD38 antibody therapy: basic science and combined immunotherapy strategies
Giovanni Martinelli
Scientific Director at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.
Topic: Importance of network in Multiple Myeloma: where are we going?
Topic: Importance of network in Multiple Myeloma: where are we going?
Alessandro Gozzetti
Hematology, University of Siena, Policlinico Le Scotte, Siena , Italy.
Topic: Daratumumab treatment for multiple myeloma patients in >VGPR but MRD positive by NGF after 1st line therapy
Topic: Daratumumab treatment for multiple myeloma patients in >VGPR but MRD positive by NGF after 1st line therapy
Daniela de Totero
Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, Italy.
Topic: The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma
Topic: The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma
Programme
Programme
- Time (GMT+2)
- Speakers
- Topic
- 5:00-5:05 PM
- Giovanni Martinelli & Claudio Cerchione
- Welcoming Speech
- 5:05-5:15 PM
- Giovanni Martinelli
- Importance of network in Multiple Myeloma: where are we going?
- 5:15-5:20 PM
- Claudio Cerchione
- Disscussion with the speaker (Q&A )
- 5:20-5:30 PM
- Carolina Terragna
- Molecular biology in myeloma
- 5:30-5:35 PM
- Giovanni Martinelli & Claudio Cerchione
- Disscussion with the speaker (Q&A )
- 5:35-5:45 PM
- Fabio Malavasi
- Anti-CD38 antibody therapy: basic science and combined immunotherapy strategies
- 5:45-5:50 PM
- Giovanni Martinelli & Claudio Cerchione
- Disscussion with the speaker (Q&A )
- 5:50-6:00 PM
- Alessandro Gozzetti
- Daratumumab treatment for multiple myeloma patients in >VGPR but MRD positive by NGF after 1st line therapy
- 6:00-6:05 PM
- Giovanni Martinelli & Claudio Cerchione
- Disscussion with the speaker (Q&A )
- 6:05-6:15 PM
- Daniela de Totero
- The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma
- 6:15-6:20 PM
- Giovanni Martinelli & Claudio Cerchione
- Disscussion with the speaker (Q&A )
- 6:20-6:30 PM
- Claudio Cerchione
- How I manage Multiple Myeloma - State of the art
- 6:20-6:30 PM
- Giovanni Martinelli
- Disscussion with the speaker (Q&A )
- 6:30-6:50 PM
- Giovanni Martinelli & Claudio Cerchione
- Free Disscussion
- 6:50-6:55 PM
- Assistant Editor
- Jounral Introduction
- 6:55-7:00 PM
- Giovanni Martinelli & Claudio Cerchione
- Conclusion Comments
Relevant special issues
Topic: Novel Agents in Multiple Myeloma: Exploring Drug Resistance and New Opportunities
https://www.oaepublish.com/specials/cdr.870Moments
Presentation
Prof. Alessandro Gozzetti
Topic: DART4MM: Daratumumab as consolidation therapy in MRD positive MM patients
NaN
Prof. Carolina Terragna
Topic：Importance of Minimal Residual Disease assessment within the bone marrow of Multiple Myeloma
NaN
Prof. Claudio Cerchione
Topic: How I manage Multiple Myeloma - State of the art
NaN
Prof. Daniela de Totero
Topic: The involvement of HGF/c-MET interaction in the pathogenesis of Multiple Myeloma and the possibility of targeting this interaction
NaN
Prof. Fabio Malavasi
Topic: CD38 in basic science and clinical practice: reflecting on the past to move to the future
NaN
Prof. Giovanni Martinelli
Topic: Importance of network in Multiple Myeloma: where are we going?
NaN
